Search Within

Hikmat Al-Ahmadie

  1. "Angela Brannon"
Formats
  1. Meeting Abstract (12)
  2. Journal Article (4)
Groups
  1. Department of Pathology and Laboratory Medicine (16)
  2. Human Oncology and Pathogenesis Program (16)
  3. Center for Molecular Imaging and Biotechnology (CMIB) (15)
  4. GSK Faculty (15)
  5. Surgery (9)
  6. Urology (9)

More Groups

People
  1. Angela Brannon (16)
  2. Michael Berger (15)
  3. Victor Reuter (12)
  4. Anuradha Gopalan (11)
  5. Samson Fine (11)
  6. Satish Tickoo (11)

More People

Years
  1. 2025 (1)
  2. 2023 (1)
  3. 2022 (1)
  4. 2021 (1)
  5. 2020 (1)
  6. 2019 (1)

More Years

Publications
  1. Laboratory Investigation (4)
  2. Modern Pathology (4)
  3. Journal of Clinical Oncology (3)
  4. American Journal of Surgical Pathology (1)
  5. Cancer Discovery (1)
  6. Cancer Research (1)

More Publications

Publishers
  1. Nature Publishing Group (4)
  2. Nature Research (4)
  3. American Association for Cancer Research (3)
  4. American Society of Clinical Oncology (3)
  5. Elsevier Science, Inc. (1)
  6. Lippincott Williams & Wilkins (1)

Results (16)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Clinical outcomes, genomic heterogeneity, and therapeutic considerations across histologic subtypes of urothelial carcinoma
    Journal Article

    Chu, C. E.; Chen, Z.; Whiting, K.; Ostrovnaya, I.; Lenis, A. T.; Clinton, T. N.; Rammal, R.; Ozcan, G. G.; Akbulut, D.; Basar, M.; more...
    European Urology (2025)

    Fulltext@MSK | Save
  • Clinical and genomic landscape of FGFR3-altered urothelial carcinoma and treatment outcomes with erdafitinib: A real-world experience
    Journal Article

    Guercio, B. J.; Sarfaty, M.; Teo, M. Y.; Ratna, N.; Duzgol, C.; Funt, S. A.; Lee, C. H.; Aggen, D. H.; Regazzi, A. M.; Chen, Z.; more...
    Clinical Cancer Research (2023)

    Fulltext@MSK | Save
  • Identifying potential mechanisms of resistance to erdafitinib (erda) via longitudinal analysis of circulating tumor (ct)-DNA of patients (pts) with advanced/metastatic urothelial cancer
    Meeting Abstract

    Guercio, B. J.; Sarfaty, M.; Teo, M. Y.; Funt, S. A.; Lee, C. H.; Aggen, D. H.; Ratna, N.; Regazzi, A. M.; Chen, Z.; Lattanzi, M.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Detection of FGFR3 alt in plasma cfDNA in metastatic UC patients receiving Erda therapy
    Meeting Abstract

    Sarfaty, M.; Teo, M. Y.; Funt, S. A.; Lee, C. H.; Aggen, D. H.; Ratna, N.; Regazzi, A. M.; Lenis, A. T.; Chen, Z.; Al-Ahmadie, H. A.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • MSK-ACCESS for the detection of fibroblast growth factor receptor-3 (FGFR3) mutations in plasma cell-free (cf)DNA of metastatic urothelial carcinoma (mUC) patients (pts) pre- and on erdafitinib (erda) therapy
    Meeting Abstract

    Sarfaty, M.; Teo, M. Y.; Funt, S. A.; Lee, C. H.; Aggen, D. H.; Ratna, N.; Regazzi, A. M.; Al-Ahmadie, H.; Brannon, A. R.; Berger, M. F.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Molecular stratification of high-grade unclassified renal cell carcinoma to improve prognostication and management strategy
    Meeting Abstract

    Chen, Y.; Di Natale, R. G.; Jayakumaran, G.; Ghanaat, M.; Marcon, J.; Brannon, A. R.; Al-Ahmadie, H.; Fine, S.; Gopalan, A.; Sirintrapun, S. J.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy
    Journal Article

    Al-Ahmadie, H.; Iyer, G.; Hohl, M.; Asthana, S.; Inagaki, A.; Schultz, N.; Hanrahan, A. J.; Scott, S. N.; Brannon, A. R.; McDermott, G. C.; more...
    Cancer Discovery (2014)

    Fulltext@MSK | Save
  • mTOR pathway activation characterizes a subset of unclassified renal cell carcinoma: Immunohistochemical, molecular and histologic analysis
    Meeting Abstract

    Kong, M. X.; Brannon, A. R. R.; Won, H.; Gandhi, A.; Al-Ahmadie, H. A.; Fine, S. W.; Gopalan, A.; Russo, P.; Berger, M. F.; Tickoo, S. K.; more...
    Modern Pathology (2014)

    Fulltext@MSK | Save
  • Hereditary leiomyomatosis and renal cell carcinoma (HLRCC)-associated renal cancer: The utility of detecting aberrant succination by immunohistochemistry
    Meeting Abstract

    Chen, Y. B.; Brannon, A. R.; Dudas, M. E.; Won, H.; Al-Ahmadie, H. A.; Fine, S. W.; Gopalan, A.; Frizzell, N.; Russo, P.; Berger, M. F.; more...
    Modern Pathology (2014)

    Fulltext@MSK | Save
  • Hereditary leiomyomatosis and renal cell carcinoma syndrome-associated renal cancer: Recognition of the syndrome by pathologic features and the utility of detecting aberrant succination by immunohistochemistry
    Journal Article

    Chen, Y. B.; Brannon, A. R.; Toubaji, A.; Dudas, M. E.; Won, H. H.; Al-Ahmadie, H. A.; Fine, S. W.; Gopalan, A.; Frizzell, N.; Voss, M. H.; more...
    American Journal of Surgical Pathology (2014)

    Fulltext@MSK | Save